Mavictoria Yangco-Gibson, PA
Physician Assistant · Miami, FLNPI 1275672842
Payments from drug & device makers
Across 85 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- Amgen$229
- Bayer$198
- GSK$186
- Johnson & Johnson$185
- Boehringer Ingelheim$183
- plus $846 from 14 others
What the payments were for
- Food & beverage$2,274100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $447 |
| Amgen | 9 | $229 |
| Bayer | 9 | $198 |
| GSK | 5 | $186 |
| Johnson & Johnson | 4 | $185 |
| Boehringer Ingelheim | 4 | $183 |
| Idorsia Pharmaceuticals US Inc | 3 | $151 |
| Sanofi-aventis U.S. LLC | 2 | $139 |
| Pfizer | 7 | $136 |
| Lilly USA, LLC | 8 | $120 |
| AbbVie | 4 | $74 |
| Amarin Pharma, Inc. | 3 | $49 |
| AstraZeneca | 2 | $38 |
| Insightec,inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Novartis | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125
- JARDIANCE$125
- TRELEGY ELLIPTA$125
- SOLIQUA 100/33$122
- RYBELSUS$118
- Repatha$111
- QUVIVIQ$108
How this compares
$2,274 in reported general payments places this provider in the 75th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $25,800 |
| EliquisApixaban | 16 | $18,892 |
| OzempicSemaglutide | 14 | $16,701 |
| TrulicityDulaglutide | 13 | $14,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,944 |
| XareltoRivaroxaban | 14 | $13,344 |
| FarxigaDapagliflozin Propanediol | 13 | $7,320 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,348 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,009 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $908 |
| Atorvastatin Calcium | 114 | $876 |
| Celecoxib | 25 | $571 |
| Rosuvastatin Calcium | 67 | $494 |
| Fluticasone Propionate | 48 | $473 |
| Lisinopril | 46 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $183 | $25,80027 claims |
| PfizerEliquis | $136 | $18,89216 claims |
| Novo NordiskOzempic | $447 | $16,70114 claims |
| Lilly USA, LLCTrulicity | $120 | $14,01713 claims |
| GSKTrelegy Ellipta | $186 | $13,94414 claims |
| Johnson & JohnsonXarelto | $185 | $13,34414 claims |
| AstraZenecaFarxiga, Symbicort | $38 | $12,66826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Miami
- Jeanelle KingMiami$424K
- Dallas GreenMiami$202K
- Paula BrezavscekMiami$127K
- Rita QuintanaMiami$110K
- Carol AntequeraMiami$98K
- Ziyad PeerMiami$89K
- Lisa DavisMiami$81K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.